Telehealth provider Hims & Hers started selling a compounded version of Novo Nordisk’s newly approved Wegovy oral formulation, prompting Novo to threaten litigation and regulatory action. Hims frames the move as expanding patient access; Novo contends the product is an unapproved, inauthentic copycat and has signaled legal remedies. Anticipated disputes will test the limits of compounding pharmacies, enforcement priorities, and intellectual property strategies around rapidly commercialized GLP-1 formulations. Legal and regulatory outcomes could set precedent for how telehealth companies market compounded versions of high-demand branded therapies.